$742.73 Million in Sales Expected for Illumina, Inc. (ILMN) This Quarter

Equities analysts predict that Illumina, Inc. (NASDAQ:ILMN) will report $742.73 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Illumina’s earnings, with the highest sales estimate coming in at $744.66 million and the lowest estimate coming in at $740.00 million. Illumina posted sales of $598.00 million during the same quarter last year, which suggests a positive year over year growth rate of 24.2%. The business is expected to report its next quarterly earnings results on Tuesday, April 24th.

According to Zacks, analysts expect that Illumina will report full-year sales of $742.73 million for the current fiscal year, with estimates ranging from $3.12 billion to $3.19 billion. For the next year, analysts expect that the firm will post sales of $3.50 billion per share, with estimates ranging from $3.34 billion to $3.66 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Illumina.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.22. The business had revenue of $778.00 million during the quarter, compared to the consensus estimate of $752.04 million. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The company’s quarterly revenue was up 25.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.85 EPS.

A number of equities analysts have issued reports on ILMN shares. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 price target for the company in a research note on Friday, October 27th. Wells Fargo & Co reiterated a “positive” rating and set a $260.00 price target (up previously from $250.00) on shares of Illumina in a research note on Tuesday, January 9th. Piper Jaffray Companies lifted their price target on Illumina to $274.00 and gave the company an “overweight” rating in a research note on Thursday, January 4th. Evercore ISI initiated coverage on Illumina in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $250.00 target price on the stock. Finally, BTIG Research initiated coverage on Illumina in a research note on Friday, January 5th. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $241.39.

In related news, SVP Oene Mark Van sold 1,408 shares of Illumina stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $228.85, for a total value of $322,220.80. Following the sale, the senior vice president now owns 15,760 shares of the company’s stock, valued at approximately $3,606,676. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $226.55, for a total transaction of $283,187.50. Following the completion of the sale, the director now directly owns 9,088 shares in the company, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. Insiders sold a total of 95,848 shares of company stock worth $21,414,125 in the last ninety days. 0.89% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the stock. Jackson Square Partners LLC raised its holdings in Illumina by 263.0% during the 4th quarter. Jackson Square Partners LLC now owns 1,034,454 shares of the life sciences company’s stock valued at $226,017,000 after acquiring an additional 749,468 shares during the period. Jennison Associates LLC raised its holdings in Illumina by 8.8% during the 4th quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock valued at $964,114,000 after acquiring an additional 355,200 shares during the period. Assenagon Asset Management S.A. raised its holdings in Illumina by 371.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 212,160 shares of the life sciences company’s stock valued at $46,355,000 after acquiring an additional 167,206 shares during the period. Carillon Tower Advisers Inc. bought a new stake in Illumina during the 4th quarter valued at $33,752,000. Finally, American Century Companies Inc. raised its holdings in Illumina by 27.4% during the 3rd quarter. American Century Companies Inc. now owns 605,149 shares of the life sciences company’s stock valued at $120,546,000 after acquiring an additional 130,038 shares during the period. 91.12% of the stock is currently owned by institutional investors.

Illumina (ILMN) traded up $7.10 during mid-day trading on Friday, reaching $233.84. The company’s stock had a trading volume of 532,175 shares, compared to its average volume of 969,668. The firm has a market cap of $34,370.00, a P/E ratio of 39.37, a P/E/G ratio of 3.01 and a beta of 0.92. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.99 and a quick ratio of 3.55. Illumina has a fifty-two week low of $158.02 and a fifty-two week high of $248.97.

ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/23/742-73-million-in-sales-expected-for-illumina-inc-ilmn-this-quarter.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply